Ernexa Therapeutics Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Ernexa Therapeutics Inc. (ERNA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-07-01.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-07-01
- Ernexa Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Ernexa Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $2.09M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K/A · filed 2022-07-01 |
| 2020-12-31 | $2.09M 10-K/A · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |